正在进行临床开发的胰岛素样生长因子受体（IGF-1R）激酶的2,4-二取代吡咯并[1,2-f][1,2,4]三嗪抑制剂（BMS-754807）的发现。
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.
作者信息
Wittman Mark D, Carboni Joan M, Yang Zheng, Lee Francis Y, Antman Melissa, Attar Ricardo, Balimane Praveen, Chang Chiehying, Chen Cliff, Discenza Lorell, Frennesson David, Gottardis Marco M, Greer Ann, Hurlburt Warren, Johnson Walter, Langley David R, Li Aixin, Li Jianqing, Liu Peiying, Mastalerz Harold, Mathur Arvind, Menard Krista, Patel Karishma, Sack John, Sang Xiaopeng, Saulnier Mark, Smith Daniel, Stefanski Kevin, Trainor George, Velaparthi Upender, Zhang Guifen, Zimmermann Kurt, Vyas Dolatrai M
机构信息
Bristol-Myers Squibb Co, Wallingford, Connecticut 06492, USA.
出版信息
J Med Chem. 2009 Dec 10;52(23):7360-3. doi: 10.1021/jm900786r.
This report describes the biological activity, characterization, and SAR leading to 9d (BMS-754807) a small molecule IGF-1R kinase inhibitor in clinical development.
本报告描述了导致9d（BMS-754807）（一种处于临床开发阶段的小分子IGF-1R激酶抑制剂）的生物学活性、特性及构效关系。
Zotero 插件